CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease

Nature Communications

Volumn 3, Issue , 2012, Pages

  Kang, Soosung ^a   Cooper, Garry ^a,b   Dunne, Sara F ^a   Dusel, Brendon ^a   Luan, Chi Hao ^a   Surmeier, D James ^b   Silverman, Richard B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CHLOROPHENETHYL) 3 CYCLOPENTYLPYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; CALCIUM CHANNEL BLOCKING AGENT; MOLECULAR SCAFFOLD; UNCLASSIFIED DRUG; 1 (3 CHLOROPHENETHYL) 3 CYCLOPENTYLPYRIMIDINE 2,4,6 (1H,3H,5H) TRIONE; 1-(3-CHLOROPHENETHYL)-3-CYCLOPENTYLPYRIMIDINE-2,4,6-(1H,3H,5H)-TRIONE; ALPHA1D (CAV1.3) L TYPE CALCIUM CHANNEL, HUMAN; ALPHA1D (CAV1.3) L-TYPE CALCIUM CHANNEL, HUMAN; BARBITURIC ACID DERIVATIVE; CALCIUM CHANNEL L TYPE;

ANTAGONISM; BRAIN; CALCIUM; DISEASE INCIDENCE; DISEASE TREATMENT; DISEASE VECTOR; MITOCHONDRION; PUBLIC HEALTH; SENSORY SYSTEM DISORDER;

ARTICLE; CELL LOSS; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ELECTROPHYSIOLOGY; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; PARKINSON DISEASE; PATCH CLAMP; STRUCTURE ACTIVITY RELATION; WHOLE CELL; ANIMAL; CELL STRAIN HEK293; CHEMISTRY; CRYSTALLOGRAPHY; DRUG EFFECT; HUMAN; METHODOLOGY; RABBIT; RAT;

ANIMALS; BARBITURATES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CRYSTALLOGRAPHY; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PARKINSON DISEASE; PATCH-CLAMP TECHNIQUES; RABBITS; RATS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84869409550     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2149     Document Type: Article

References (23)

1. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368-376 (2008). (Pubitemid 351441488)
2. Fearnley, J. M. & Lees, A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114, 2283-2301 (1991).
3. Riederer, P. & Wuketich, S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of infuential factors in human brain amine analysis. J. Neural. Transm. 38, 277-301 (1976).
4. Casamassima, F. et al. L-type calcium channels and psychiatric disorders: a brief review. Am. J. Med. Genet. Part B 153B, 1373-1390 (2010).
5. Chan, C. S. et al. 'Rejuvenation protects neurons in mouse models of Parkinson's disease. Nature 447, 1081-1086 (2007). (Pubitemid 47014425)
6. Guzman, J. N. et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696-700 (2010).
7. Guzman, J. N., Sánchez-Padilla, J., Chan, C. S. & Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011-11009 (2009).
8. Triggle, D. J. 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell Mol. Neurobiol. 23, 293-303 (2003). (Pubitemid 36676276)
9. Epstein, M. Calcium antagonists: still appropriate as frst line antihypertensive agents. Am. J. Hypertens. 9, 110-121 (1996). (Pubitemid 26108111)
10. Becker, C., Jick, S. S. & Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology 70, 1438-1444 (2008). (Pubitemid 351521937)
11. Ritz, B. et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600-606 (2010).
12. 1 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J. Neurosci. 21, 5944-5951 (2001). (Pubitemid 32737727)
13. Catterall, W. A., Perez-Reyes, E., Snutch, T. P. & Striessnig, J. International Union of Pharmacology XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57, 411-425 (2005). (Pubitemid 43036432)
14. Lipscombe, D., Helton, T. D. & Xu, W. L-type calcium channels: the low down. J. Neurophysiol. 92, 2633-2641 (2004). (Pubitemid 40340475)
15. Sinnegger-Brauns, M. J. et al. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol. Pharmacol. 75, 407-414 (2009).
16. Triggle, D. J. et al. Synthetic organic ligands active at voltage-gated calcium channels. Ann. N Y Acad. Sci. 635, 123-138 (1991).
17. Triggle, D. J. L-type calcium channels. Curr. Pharmaceut. Des. 12, 443-457 (2006).
18. Sullivan, E., Tucker, E. M. & Dale, L. Measurement of [Ca2+] using the fuorometric imaging plate reader (FLIPR). Meth. Mol. Biol. 114, 125-33 (1999).
19. Minta, A., Kao, J. P. Y. & Tsien, R. Y. Fluorescent indicators for cytosolic calcium based on rhodamine and fuorescein chromophores. J. Biol. Chem. 264, 8171-8178 (1989). (Pubitemid 19137304)
20. V1.2. Bioorg. Med. Chem. 18, 3147-3158 (2010).
21. Xia, G. et al. Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J. Med. Chem. 54, 2409-2421 (2010).
22. Wöhler, F. On the artifcial formation of urea. Ann. Phys. Chem. 88, 253-256 (1828).
23. Biltz, H. & Wittek, H. Darstellug von Barbitursaure und N-Alkyl-barbitursauren. Chem. Ber. 54, 1035-1058 (1921).